Clinical trials
Hereditary Breast and Ovarian Cancer clinical trials
Below are recruiting hereditary breast and ovarian cancer clinical trials, each written for real people, not researchers. We’re tracking 23 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03050268Recruiting
Study of childhood cancer risk in families
This study looks at inherited (family) risk for childhood cancers, including families with early cancers or known cancer risk conditions. It may help researchers understand why some children get cancer and improve future risk detection and care.
Memphis, TennesseeAges Any age - NCT03124212Recruiting
Genetic testing guidance for inherited breast, ovarian, or colon cancer risk
This study helps people in Switzerland who already have a known inherited cancer gene change understand what it means for them and their family. It focuses on people with specific known mutations related to hereditary breast/ovarian cancer and Lynch syndrome.
Fribourg, Canton of FribourgAges 18 years+ - NCT04494945Recruiting
Help for people with inherited cancer risk genes
This study helps identify people who may have an inherited cancer risk and checks how best to support them. Depending on the group, you may only fill out surveys, or you may also create an app account and possibly provide a DNA sample.
Portland, OregonAges 18 years+ - NCT05130606Recruiting
Story-based program to improve genetic cancer counseling for Latina women
This study tests a Spanish/English narrative (story-based) program designed to help improve genetic counseling and genetic testing for hereditary breast and ovarian cancer risk. It may help you better understand your options and feel more prepared to get the right type of genetic care.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05649072Recruiting
Mobile mammogram screening study for women with family cancer risk
This study looks at how well mobile mammogram units and video/phone genetics counseling (“telegenetics”) can help women who may have inherited cancer risk. If you’re scheduled for a mammogram through the Project VALET mobile units, this may be an easy option to learn about and address your risk.
Houston, TexasAges 18 years+ - NCT06735326RecruitingPhase 2
Fluzoparib and Bevacizumab Before Surgery for Advanced Ovarian Cancer
This trial tests whether combining fluzoparib (a PARP inhibitor) with or without bevacizumab (a blood vessel growth blocker) before surgery can shrink advanced ovarian cancer. It is for women with a BRCA gene mutation whose cancer cannot be fully removed with surgery right now.
Jinan, ShandongAges 18 years+ - NCT06892275Recruiting
Helping high-risk women decide about breast MRI
This study tests a decision aid to help women at high risk for breast cancer decide whether to get a screening MRI. It is designed for Black and Latina women who have had a normal mammogram in the past year.
Washington D.C., District of ColumbiaAges 18–74 - NCT07039552Recruiting
Ovarian cancer risk check for family members
This study looks at family members of people with ovarian cancer to build a better tool for predicting their risk. If you have a BRCA1 or BRCA2 gene mutation, you may be able to join.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07270679Recruiting
Genetic markers for ovarian damage after chemo
This study is looking for genetic markers that may help predict how chemotherapy affects the ovaries. It's for women who had breast cancer or lymphoma, froze their ovarian tissue before treatment, and finished that treatment at least 6 months ago.
Bologna, BolognaAges 18–38 - NCT02302742Recruiting
Registry for triple-negative breast cancer and inherited mutation carriers
This registry studies people with triple-negative breast cancer or inherited “HBOC” gene mutations (like BRCA, PALB2, PTEN, TP53). It collects information to better understand risk, outcomes, and how these cancers behave—helping future research and care.
Hays, KansasAges Any age - NCT07532434Recruiting
Risk-Reducing Surgery for Hereditary Ovarian Cancer
This study follows women who carry gene mutations that increase ovarian cancer risk to understand how preventive surgery affects their health, quality of life, and peace of mind. Researchers will track your outcomes over 3 years to help inform future treatment decisions for others at similar risk.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07381985Enrolling by invitation
Managing hereditary cancer risk in rural areas
This study tests a way to help people with inherited cancer gene mutations manage their health, especially if they live in rural areas. You join if you found out about the mutation more than a year ago.
Burlington, VermontAges 18 years+ - NCT00539162Recruiting
CA-125 and other tests to check for early ovarian cancer risk
This study looks at how well a blood test called CA-125, along with other markers and checkups, can detect ovarian cancer early. It’s for women considered low risk who will do regular blood tests and possibly a vaginal ultrasound if results suggest it.
Miami, FloridaAges 50–74 - NCT07237256RecruitingPhase 3
Testing less chemo for HR+ HER2- breast cancer with ribociclib
This trial tests whether some people with hormone receptor-positive, HER2-negative early breast cancer can safely receive less chemotherapy when also taking the targeted drug ribociclib after surgery. You may qualify if you have a specific stage of breast cancer and are planning to take hormone therapy for at least 5 years.
AmiensAges 18 years+ - NCT07033819RecruitingPhase 2
Fuzuloparib and apatinib before surgery for ovarian cancer
This trial tests a combination of two oral drugs—fuzuloparib (a PARP inhibitor) and apatinib (which blocks blood vessel growth to tumors)—given before surgery for advanced ovarian cancer that cannot be removed right away. It is for people whose tumors have a specific genetic marker (HRD positive) and who have not had prior cancer treatment.
Beijing, Beijing MunicipalityAges 18–70 - NCT06953882RecruitingPhase 2
Skipping chemo after surgery for ER+ HER2- breast cancer
This study tests whether some people with a certain type of breast cancer (ER-positive, HER2-negative) can safely skip chemotherapy. After surgery, they receive a targeted pill (ribociclib) plus hormone therapy instead. The goal is to see if this approach works just as well with fewer side effects.
New Haven, ConnecticutAges 18 years+ - NCT07380646RecruitingPhase 2
Leucogen to prevent low white blood cells from ribociclib in early breast cancer
This trial tests if Leucogen can prevent neutropenia (low white blood cells) caused by ribociclib, a targeted therapy for hormone receptor-positive, HER2-negative early breast cancer. It may help you stay on treatment without delays or dose reductions.
Hangzhou, ZhejiangAges 18 years+ - NCT06073626Recruiting
Genetic testing study for Black cancer survivors
This study offers free genetic testing to Black or African American people who have had certain cancers. It aims to find inherited gene changes that increase cancer risk and improve health equity.
Washington D.C., District of ColumbiaAges 18–80 - NCT06861621Recruiting
Genetics study for hereditary cancer risk
This study looks at genetic changes linked to breast, ovarian, or digestive cancers. It may help doctors better understand inherited cancer risks.
CaenAges 18 years+ - NCT06726642Recruiting
Blood test study for people with inherited cancer risk
This study looks for DNA fragments in blood of people with certain inherited cancer syndromes. It may help find cancer earlier or guide better monitoring. You would give blood samples every 4 months (if in the experimental group).
Vancouver, British ColumbiaAges Up to 90 years - NCT06312124Recruiting
Fallopian tube removal to prevent ovarian cancer
This study looks at removing fallopian tubes during other planned surgeries to help prevent ovarian cancer. You may be able to join if you are at least 45 years old, are female or assigned female at birth, and are having non-gynecologic surgery (like gallbladder or hernia repair).
Baltimore, MarylandAges 45 years+ - NCT03854110RecruitingPhase 1
Testing a new drug for ovarian cancer that resists platinum chemo
This trial studies a new drug, misetionamide, given alone or with gemcitabine, for people with ovarian, fallopian tube, or primary peritoneal cancer that no longer responds to platinum-based chemotherapy. The goal is to see if the drug is safe and if it can help shrink or control the cancer.
Chicago, IllinoisAges 18 years+ - NCT04743479Recruiting
AI screening for pancreatic cancer in higher-risk people
This trial uses an artificial-intelligence tool to help detect pancreatic cancer earlier and track people at higher risk. You may be asked to complete questionnaires and have imaging tests like MRI or CT to see how well the approach works.
ShanghaiAges 50–75
Hear when a new Hereditary Breast and Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hereditary breast and ovarian cancer?
- Yes. Clin2 currently lists 23 recruiting hereditary breast and ovarian cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hereditary breast and ovarian cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hereditary breast and ovarian cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.